RELEASE: metabion expands capacity to produce diagnostic and therapeutic oligonucleotides in East Munich

Investment in double digit million euros completed in the first quarter of 2023 - Applications in diagnostic and therapeutic solutions - Wide range of services from CMO to medium/large scale (c) GMP manufacturing.

RELEASE: metabion expands capacity to produce diagnostic and therapeutic oligonucleotides in East Munich

Investment in double digit million euros completed in the first quarter of 2023 - Applications in diagnostic and therapeutic solutions - Wide range of services from CMO to medium/large scale (c) GMP manufacturing

MUNICH, July 11, 2023/PRNewswire/ -- metabion has increased its global production capacity for newly introduced therapeutic and diagnostic oligonucleotides and their derivatives to meet growing demand in Europe and around the world. In the past two years, the company has planned, built, and established a state-of-the-art oligonucleotide manufacturing facility dedicated to manufacturing small, medium, and large-scale oligonucleotide components for in vitro diagnostic (IVD)/specific reagents. Analytes (ASR) oligonucleotides and medium to large scale oligonucleotides for R&D and therapeutic applications.

The investment is in the range of two-digit million euros and includes state-of-the-art clean room areas classified ISO 8 and 7. The standards applied and certified are ISO 9001:2015, ISO 13485:2016 and EXCiPACT® GMP/GDP:2021 .

"With this investment, we are strengthening our CMO segment and are committed to further expanding our growing business area," said Dr. Regina Bichlmaier, CEO of metabion. "At the same time, we are responding to an increasing demand for highly customized diagnostic solutions, including packaging/kitting/OEM services and supporting early-stage oligonucleotide-based drug development, from lead discovery and optimization through to preclinical development in clinical phases I and II.We are proud to say that our newly established and outstanding state-of-the-art production site east of Munich will enable us to offer "best metabion value" for small, medium and small oligonucleotide requirements. and large scale with respect to experience, capabilities, customization, and flexibility."

"We want to drive growth in the custom oligonucleotide business with our strong customer focus integrated by metabion," said Dr. Heike Koepf, Head of Sales and Quality Management. "In doing so, we aim to intensify our collaboration with customers in Europe and expand our product portfolio to stakeholders globally."

About Metabion:

metabion is one of the world's leading manufacturers of high quality custom oligonucleotides. With its vast experience and innovative technologies, processes and methods, the company is a "boutique" and the most comprehensive provider of custom oligos in the world. Best-in-class in providing high-quality products and services in accordance with the motto "quantity meets quality" and following our vision of being the premier provider of custom oligonucleotide services, dedicated to improving the scientific progress and support diagnostic and therapeutic solutions.

metabion international AG | Semmelweisstrasse 3 | 82152 Planegg/Steinkirchen | Germany phone: 49 89 899 363 0 | fax: 49 89 899 363 11 | e-mail: info@metabion.com | www.metabion.com

Logo - https://mma.prnewswire.com/media/2150661/mb_Logo_InThisTogether_300dpi_Logo.jpg

View original content: https://www.prnewswire.com/news-releases/metabion-amplia-la-capacidad-de-producir-oligonucleotidos-diagnosticos-y-terapeuticos-en-el-este-de-munich-301874477.html

NEXT NEWS